Albuquerque, N.M., March 8, 2017 – Lovelace Biomedical, a not-for-profit preclinical contract research organization, today announced its participation in and presentation of scientific data at the Society of Toxicology (SOT) 56th Annual Meeting, held March 12 to 16 in Baltimore. This announcement comes on the heels of launching Lovelace Biomedical to partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, highlighting its shift in focus and expertise in general and specialty toxicology.
As Lovelace Biomedical expands its footprint in toxicology service offerings, some are asking: Why general toxicology, and why now? Here, we get the answers from Dr. Matthew Reed, a board-certified toxicologist and Lovelace’s Vice President of Applied Toxicology and Nonclinical Development
As you prepare to launch ambitious new projects in 2017, I’d like to personally encourage you to explore the wide array of services and expertise Lovelace Biomedical provides in toxicology, pharmacology, formulation and more. While Lovelace is the same not-for-profit CRO you’ve always known—with a deep history of excellence in respiratory research—today, we offer much more.
The Lovelace Respiratory Research Institute, including the commercially-focused CRO arm Lovelace Biomedical, has been a leader in inhalation drug delivery, respiratory disease and development of aerosol formulations for more than 40 years. This year, Lovelace will showcase this broad expertise as the host organization for the 21st Congress of the International Society for Aerosols in […]
Lovelace Biomedical welcomes Dr. Larry Mallis as Director of Bioanalytical Operations and a key member of the scientific leadership team. Larry received his Ph.D. in Analytical Chemistry and Mass Spectrometry from Texas A & M University and is a 30 year veteran of analytical chemistry and mass spectrometry in the pharmaceutical and agrochemical industries. He […]
While the concept of gene therapy has been around for decades, gene therapy companies are just beginning to convert the promise of gene therapy into reality for patients suffering from a variety of rare diseases and cancer, among others. The gene therapy industry went into dormancy after a high profile patient death in 1999 but […]